Antipermeability and antiproliferative effects of standard and frozen bevacizumab on choroidal endothelial cells

BACKGROUND: Bevacizumab is an antiangiogenic compound developed to target tumour vessels. Its off‐label use in ophthalmology requires in vitro testing on ocular cells. AIM: To quantify the antipermeability and antiproliferative effects of bevacizumab on cultured choroidal endothelial cells (CECs). I...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Peters, Swaantje, Julien, Sylvie, Heiduschka, Peter, Grisanti, Salvatore, Ziemssen, Focke, Adler, Martin, Schraermeyer, Ulrich, Bartz‐Schmidt, Karl‐Ulrich
Formato: Artigo
Idioma:Inglês
Publicado: BMJ Group 2007
Assuntos:
Extended Report
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC1955593/
https://ncbi.nlm.nih.gov/pubmed/17179166
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bjo.2006.109702
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares